Bluejay Diagnostics (NASDAQ:BJDX) said it has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6) for its Symphony™ cartridge program, marking a development milestone for the diagnostic platform.
The company, which trades on the Nasdaq under the ticker BJDX, said the production milestone was achieved on Dec. 29, 2025.
Internal testing showed that both antibody types met the company’s performance criteria for reactivity and their intended diagnostic use.
Bluejay said the antibodies were produced using a combination of third-party and proprietary immunogens.
While third-party immunogens supported the current production run, the company plans to rely on its proprietary immunogen for ongoing development and to strengthen its intellectual property strategy.
The company estimated that its existing antibody inventory is sufficient to support the manufacture of more than nine million Symphony cartridges and said it has the capability to produce additional antibodies as needed to meet future demand.
Bluejay emphasized that the Symphony cartridge system remains under development and will be subject to further validation and regulatory review before any potential commercialization.